RecruitingNot ApplicableNCT07572773

CHAMP Lung Cancer Screening Program

CHAMP: Community Health Assessment and Monitoring in the Pharmacy. Assessing the Impact of a Community Pharmacist Lung Cancer Screening (LCS) Program

Sponsor

Jill Kolesar

Enrollment

300 participants

Start Date

Jun 12, 2026

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Early Lung Cancer Detection

Summary

The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barriers include the complexity of screening and competing demands in primary care. To address these challenges, investigators propose a two-part intervention: a blood-based screening test to simplify LCS and a community pharmacist-led referral program integrated into routine pharmacy care. Eligible patients will be identified at Greenwood Pharmacy in Waterloo, Iowa. Interested individuals will be consented by a pharmacist and engaged in shared decision-making about LCS. Participants may decline screening, complete the DELFI Diagnostics FirstLook lung cancer screening blood test, or pursue CT screening through their primary care physician. Those choosing the blood test will be referred to Cedar Valley Family Medicine. Patients with a positive result will complete a standard shared decision-making visit with their PCP and, if appropriate, undergo confirmatory CT imaging. Patients with a negative result will enter a screening cohort and be re-screened annually for an additional year.

Eligibility

Min Age: 50 YearsMax Age: 77 Years

Inclusion Criteria4

aged 50-77
smoking pack-year history of ≥ 20 years
current smoker or quit smoking 15 or less years ago
ability to understand and willingness to sign a written informed consent document

Exclusion Criteria2

self-report of lung cancer screening in the last 12 months
psychiatric illness/social situations that would limit compliance with study requirements

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTDELFI Diagnostics FirstLook Lung Cancer Screening Blood Test

A participant can choose to receive this test. This is done by receiving a blood draw. The blood sample is sent to the DELFI Diagnositics lab without any personal health information attached. Results will be relayed to the participant as either "elevated" or "not elevated". IF the result is "elevated" the participant will be recommended to receive a low-dose CT scan.

DIAGNOSTIC_TESTLow-Does CT Scan

If a participant chooses this arm, the participant will request their primary care physician to order them a low-dose CT scan as part of the USPSTF standards for lung cancer screening. Participants will be asked to fax the results of those scans to the study.